| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -31.83% | 11.47% | -21.54% | -57.47% | -65.50% | -104.46% | -185.27% | -114.15% | -111.03% | -4920.31% | -17572.55% | -1371.21% |
| EBITDA Margin | -29.81% | 13.45% | -17.97% | -52.98% | -60.08% | -99.47% | -177.25% | -110.08% | -105.80% | -4816.81% | -17153.79% | -1333.39% |
| Net Margin | -32.45% | 12.37% | -43.11% | -75.40% | -59.66% | -102.60% | -187.77% | -120.22% | -32.79% | -4930.18% | -17560.26% | -1391.71% |
| Current Ratio | 2.32 | 4.20 | 3.95 | 4.13 | 5.75 | 5.97 | 5.55 | 8.21 | 13.91 | 4.95 | 3.60 | 6.72 |
| Quick Ratio | 1.48 | 3.18 | 3.45 | 3.80 | 5.34 | 5.42 | 4.90 | 7.49 | 12.96 | 4.78 | 3.60 | 6.72 |
| Debt / Equity | 0.73 | 0.74 | 1.56 | 4.01 | 0.61 | — | — | 0.41 | 0.76 | 0.05 | 0.14 | 0.01 |
| ROE | -62.55% | 15.40% | -62.37% | -182.75% | -45.13% | -72.74% | -87.40% | -35.06% | -6.42% | -79.38% | -115.59% | -54.83% |
| ROA | -21.30% | 5.94% | -16.42% | -22.49% | -13.30% | -18.57% | -39.23% | -22.04% | -3.88% | -63.02% | -80.37% | -46.03% |
| Asset Turnover | 0.66 | 0.48 | 0.38 | 0.30 | 0.22 | 0.18 | 0.21 | 0.18 | 0.12 | 0.01 | 0.00 | 0.03 |
| Book Value / Share | 11.39 | 14.16 | 9.30 | 4.40 | 11.42 | 9.77 | 11.11 | 15.58 | 13.42 | 6.91 | 4.50 | 6.19 |
Sarepta Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and marketing therapies for rare diseases, with a strong emphasis on genetic and neuromuscular disorders. The company’s current portfolio includes approved treatments for Duchenne muscular dystrophy, alongside research programs in RNA-based medicines, gene therapy, and other genetic modalities. Sarepta Therapeutics also advances a broader pipeline for rare muscle and central nervous system diseases, reflecting its specialization in precision medicines for underserved patient populations. Its products and development efforts position the company as a notable participant in the rare-disease therapeutics market, where specialized science and targeted treatments are central to clinical and commercial activity.